PDF(Pubmed)
Abstract：
The study aimed to investigate the potential of low dose chitooligosaccharide (COS) in ameliorating dextran sodium sulfate (DSS) induced chronic colitis by regulating microbial dysbiosis and pro-inflammatory responses. Chronic colitis was induced in BALB/c mice by DSS (4% w/v, 3 cycles of 5 days) administration. The mice were divided into four groups: vehicle, DSS, DSS + mesalamine and DSS+COS. COS and mesalamine were administered orally, daily once, from day 1 to day 30 at a dose of 20 mg/kg and 50 mg/kg respectively. The disease activity index (DAI), colon length, histopathological score, microbial composition, and pro-inflammatory cytokine expression were evaluated. COS (20 mg/kg, COSLow) administration reduced the disease activity index, and colon shortening, caused by DSS significantly. Furthermore, COSLow restored the altered microbiome in the gut and inhibited the elevated pro-inflammatory cytokines (IL-1 and IL-6) in the colon against DSS-induced chronic colitis in mice. Moreover, COSLow treatment improved the probiotic microflora thereby restoring the gut homeostasis. In conclusion, this is the first study where microbial dysbiosis and pro-inflammatory responses were modulated by chronic COSLow treatment against DSS-induced chronic colitis in Balb/c mice. Therefore, COS supplementation at a relatively low dose could be efficacious for chronic inflammatory bowel disease.
摘要：
本研究旨在探讨低剂量壳寡糖（COS）通过调节微生物菌群失调和促炎反应改善葡聚糖硫酸钠（DSS）诱导的慢性结肠炎的潜力。DSS诱导BALB/c小鼠慢性结肠炎(4%w/v，3个周期的5天）给药。将小鼠分为四组：赋形剂，DSS,DSS+美沙拉嗪和DSS+COS。口服COS和美沙拉嗪，每天一次,从第1天到第30天,分别以20mg/kg和50mg/kg的剂量。疾病活动指数（DAI），结肠长度,组织病理学评分,微生物组成，评估促炎细胞因子的表达。COS（20mg/kg，COSLow）给药降低了疾病活动指数，结肠缩短，由DSS引起的显著。此外，COSLow恢复了肠道中改变的微生物组，并抑制了结肠中升高的促炎细胞因子（IL-1和IL-6），以对抗DSS诱导的小鼠慢性结肠炎。此外，COSLow治疗改善了益生菌菌群，从而恢复了肠道稳态。总之,这是第一项通过慢性COSLow治疗Balb/c小鼠DSS诱导的慢性结肠炎来调节微生物菌群失调和促炎反应的研究.因此,以相对低的剂量补充COS对于慢性炎症性肠病可能是有效的。
